Merck & Co., Inc. (MRK) — closed signal from October 1, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 30, 2025 — +24.2% at the close.
Predicted vs. what happened
What happened
Reached its target in 48 days.
The thesis — published October 1, 2025
Merck is a steady, dividend-paying healthcare name. European drugmakers rose after Pfizer struck a pricing deal, which helped the group, including Merck. Near-term price action looks a bit heated, so patience can help. Over the next 0-3 months, the idea is to buy on pullbacks rather than paying up, and avoid chasing quick run-ups before the company's Q3 updates.
Primary drivers
- Healthcare stocks climbed after Pfizer reached a drug pricing deal in Europe
- Shares have been firm, and the dividend adds steady income with lower swings
- Blockbuster cancer drug Keytruda and a strong vaccine lineup anchor reliable sales
- Prefer buying on down days rather than paying up after quick, heated run-ups
How it played out
MRK: target reached in 48 days
Lyra published MRK at $85.39 on 2025-10-01 with 12% expected growth over a short-term window. The thesis pointed to healthcare stocks rising after Pfizer reached a drug pricing deal in Europe, Merck's dividend profile, Keytruda, its vaccine lineup, and a preference for buying pullbacks instead of chasing quick run-ups.
Inside the window, MRK reached the $94.83 target in 48 days. The peak was $107.59 on 2025-12-29, with a 26% gain at the high. The stock ended the window at $106.06. The published thesis played out, and price moved well past the target before the window closed.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.